



# *Article* **Calcium/P53/Ninjurin 1 Signaling Mediates Plasma Membrane Rupture of Acinar Cells in Severe Acute Pancreatitis**

**Chehao Lee † , Guang Xin † , Fan Li, Chengyu Wan, Xiuxian Yu, Lijuan Feng, Ao Wen, Yu Cao and Wen Huang \***

Department of Emergency Medicine and Laboratory of Ethnopharmacology, Tissue-Orientated Property of Chinese Medicine Key Laboratory of Sichuan Province, West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, China

**\*** Correspondence: huangwen@scu.edu.cn; Tel.: +86-028-8516-4076

† These authors contributed equally to this work.

**Abstract:** Ninjurin 1 (NINJ1) is a double-transmembrane cell-surface protein that might mediate plasma membrane rupture (PMR) and the diffusion of inflammatory factors. PMR is a characteristic of acinar cell injury in severe acute pancreatitis (SAP). However, the involvement of NINJ1 in mediating the PMR of acinar cells in SAP is currently unclear. Our study has shown that NINJ1 is expressed in acinar cells, and the expression is significantly upregulated in sodium-taurocholate-induced SAP. The knockout of NINJ1 delays PMR in acinar cells and alleviates SAP. Moreover, we observed that NINJ1 expression is mediated by  $Ca^{2+}$  concentration in acinar cells. Importantly, we found that  $Ca^{2+}$ overload drives mitochondrial stress to upregulate the P53/NINJ1 pathway, inducing PMR in acinar cells, and amlodipine, a  $Ca^{2+}$  channel inhibitor, can reduce the occurrence of PMR by decreasing the concentration of  $Ca^{2+}$ . Our results demonstrate the mechanism by which NINJ1 induces PMR in SAP acinar cells and provide a potential new target for treatment of SAP.

**Keywords:** nerve-injury-induced protein 1; plasma membrane rupture; severe acute pancreatitis



**Citation:** Lee, C.; Xin, G.; Li, F.; Wan, C.; Yu, X.; Feng, L.; Wen, A.; Cao, Y.; Huang, W. Calcium/P53/Ninjurin 1 Signaling Mediates Plasma Membrane Rupture of Acinar Cells in Severe Acute Pancreatitis. *Int. J. Mol. Sci.* **2023**, *24*, 11554. [https://doi.org/](https://doi.org/10.3390/ijms241411554) [10.3390/ijms241411554](https://doi.org/10.3390/ijms241411554)

Academic Editor: Zoltán Rakonczay

Received: 7 May 2023 Revised: 11 July 2023 Accepted: 14 July 2023 Published: 17 July 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license [\(https://](https://creativecommons.org/licenses/by/4.0/) [creativecommons.org/licenses/by/](https://creativecommons.org/licenses/by/4.0/)  $4.0/$ ).

# **1. Introduction**

Acute pancreatitis (AP) is a digestive system disease associated with pancreatic inflammation and edema [\[1\]](#page-15-0). It can be classified into different categories based on severity: mild acute pancreatitis without necrosis or organ failure, moderate pancreatitis with sterile necrosis or transient organ failure, moderately severe acute pancreatitis with infected necrosis or persistent organ failure, and severe acute pancreatitis (SAP) with infected necrosis and persistent organ failure [\[2,](#page-15-1)[3\]](#page-15-2). Various factors, such as gallstones, alcoholism, and hyperlipidemia, can contribute to the development of AP [\[1\]](#page-15-0). The worldwide annual incidence of acute pancreatitis is 34 cases per 100,000 individuals, with an average annual percentage increase of 3.07% [\[4](#page-15-3)[,5\]](#page-15-4). Conventional treatment for pancreatitis usually includes drainage, the administration of antibiotics or the surgical removal of necrotic tissue, dietary control, pain management, or fluid replacement. However, the majority of these treatments are symptomatic, and our understanding of the underlying causes, such as gallstones or alcohol abuse, remains limited [\[6](#page-15-5)[,7\]](#page-15-6). Approximately 20% of AP cases may progress to SAP, which is characterized by plasma membrane rupture (PMR), the release of damage-associated molecular patterns (DAMPs), and inflammatory factors. This condition can lead to a high mortality rate, making SAP a significant clinical challenge as it lacks an effective pharmacological treatment option due to the limited understanding of its causes and underlying mechanisms [\[8,](#page-15-7)[9\]](#page-15-8).

Ninjurin1 (NINJ1) was initially identified as a transmembrane protein that is upregulated in response to nerve injury [\[10\]](#page-15-9). NINJ1 has been recognized as a mediator of immune cells by facilitating cell adhesion through homophilic interactions and interaction of the same protein, mediated by its amino acid 26-37 domain [\[11\]](#page-16-0). Recent studies have reported the involvement of NINJ1 in PMR [\[12\]](#page-16-1), which is a critical event in the development of

SAP. The recruitment of immune cells and the occurrence of PMR have a significant impact on the progression of SAP. However, the role of NINJ1 in pancreatic acinar cells and its relationship with SAP are still not fully understood.

 $Ca<sup>2+</sup>$  overload is a key event in the development of SAP, which can result in cell necrosis and ultimately lead to PMR [\[8](#page-15-7)[,13\]](#page-16-2). The endoplasmic reticulum (ER) functions as an intracellular  $Ca^{2+}$  reservoir in acinar cells and plays a crucial role in regulating intracellular  $Ca<sup>2+</sup>$  levels. Stimulation by bile acids can trigger the release of  $Ca<sup>2+</sup>$  from ER into the cytosol through  $Ca^{2+}$  inositol 1,4,5-trisphosphate receptor (IP3R) channels, a member of the family of intracellular calcium release channels located in the ER  $[8]$ . As a result, a massive amount of stored  $Ca^{2+}$  is released from the ER into the cytoplasm. This accumulation activates calcium-release-activated calcium modulator 1 (Orai1), facilitating the entry of extracellular  $Ca<sup>2+</sup>$  into acinar cells, resulting in persistent cytoplasmic  $Ca<sup>2+</sup>$  overload [\[13\]](#page-16-2). Such an overload can contribute to the premature activation of trypsin, production of inflammatory cytokines, and mitochondrial stress [\[14\]](#page-16-3). Finally, acinar cell PMR could induce cellular necrosis [\[15\]](#page-16-4).  $Ca^{2+}$  and NINJ1 can eventually contribute to PMR; however, the correlation between  $Ca^{2+}$  and NINJ1 is still unclear.

Elevated cytoplasmic  $Ca^{2+}$  levels can activate the mitochondrial calcium uniporter (MCU) and induce the transfer of  $Ca^{2+}$  into the mitochondria. The primary physiological role of mitochondria in the cell is to synthesize ATP, which provides energy for cellular life activities. The continuous redox reactions and electron transport chain in the inner mitochondrial membrane result in a potential difference between the inner and outer mitochondrial membranes, known as the mitochondrial membrane potential (∆Ψm) [\[8](#page-15-7)[,13\]](#page-16-2). The excessive influx of  $Ca^{2+}$  can also lead to mitochondrial dysfunction, oxidative stress, and cellular damage [\[16\]](#page-16-5). Additionally, excessive ROS could induce DNA damage and contribute to the upregulation of P53 expression [\[17\]](#page-16-6). It receives various signals related to cellular health and determines whether to initiate cell division. If the cell is irreparably damaged, P53 triggers apoptosis or necrosis [\[18](#page-16-7)[–20\]](#page-16-8). Interestingly, activated P53 binds to the promoter region of NINJ1, which leads to the upregulation of NINJ1 expression [\[21\]](#page-16-9). Therefore,  $Ca^{2+}$  overload can promote mitochondrial stress and induce P53 to regulate NINJ1.

Amlodipine (AML) is a dihydropyridine  $Ca^{2+}$  channel blocker, which is commonly used to treat hypertension and angina by relaxing blood vessels and reducing the workload on the heart [\[22\]](#page-16-10). It can also prevent heart and blood vessel problems such as heart attacks and strokes. Recent studies have shown that AML may reduce the expression of NINJ1 in endothelial cells [\[23\]](#page-16-11), but they did not explain how NINJ1 is affected from the perspective of  $Ca^{2+}$ .

The aim of this study is to investigate the underlying mechanisms of SAP and explore the role of NINJ1 in pancreatic acinar cells and its relationship with  $Ca^{2+}$  overload. The study aims to obtain a deeper understanding of the involvement of  $Ca^{2+}$  and NINJ1 in the inflammatory process of pancreatitis, providing scientific evidence for the development of novel therapeutic strategies for SAP.

#### **2. Results**

# *2.1. NINJ1 Is Expressed and Activated in SAP Acinar Cells*

To confirm the expression of NINJ1 in acinar cells, primary mouse acinar cells were extracted and incubated with sodium taurocholate (STC) for 50 min to establish an in vitro model of SAP. Immunofluorescence staining was performed to detect the expression of NINJ1; the results demonstrated that NINJ1 was expressed in acinar cells, and its expression was significantly upregulated in the STC group (Figure [1A](#page-2-0),B). This finding that NINJ1 is expressed in acinar cells suggests that it may play a role in the pathogenesis of SAP.

<span id="page-2-0"></span>

**Figure 1.** NINJ1 accumulates on STC-SAP mouse acinar cells and affects PMR. (**A**) Primary mouse **Figure 1.** NINJ1 accumulates on STC-SAP mouse acinar cells and affects PMR. (**A**) Primary mouse acinar cell treated with 5 mM STC for 50 min, then stained with IF. IF: NINJ1 observed; scale bar = 100  $\mu$ m. (**B**) The quantitative plot of NINJ1 fluorescence levels (*n* = 5). (**C**) NINJ1<sub>26-37</sub> was  $t_{\text{tot}}$  is the distribution of  $\alpha$  and  $\alpha$  and  $\alpha$  matrice times in the SAP model  $\alpha$  model in the SAP model in t intraperitoneally injected before modeling (3 and 6 mg/kg), once a day, three times in total; the SAP model was induced by retrograde injection of 3.5% STC into the pancreaticobiliary duct. Samples were taken 24 h later. Yellow square = enlarged area. White arrow = oligomerization. Scale bar = 100 μm. **(D)** The quantitative plot of NINJ1 fluorescence levels.  $(n = 3)$ . **(E)** Mouse pancreatic acinar cells 266-6 were photographed using HCS real-time imaging. Scale bar = 50 µm. (**F**) An HCS data analysis system was used to analyze the changes in the cell perimeter at different time points. SAP: severe acute pancreatitis, STC: sodium taurocholate, PMR: plasma membrane rupture, IF: immunofluorescence, .<br>HCS: high-content screening. All data are presented as mean  $\pm$  SEM; \* *p* < 0.05, \*\* *p* < 0.01 vs. the *2.2. NINJ1 Knockout Inhibits PMR of Acinar Cells and Ameliorated SAP* control group.  $\frac{h}{p}$   $\lt$  0.05 vs. the STC group.

To investigate the function of NINJ1, NINJ1<sub>26-37</sub> (a blocking peptide) is utilized to block the NINJ1-adhesive fragment sequence of NINJ1 [\[24\]](#page-16-12), which has been reported to inhibit platelet PMR [\[25\]](#page-16-13). A primary acinar cell necrosis experiment was conducted to examine the effect of NINJ1<sub>26-37</sub> on STC-SAP acinar cells. The results demonstrated that the STC group induced acinar cell necrosis, while the NINJ1<sub>26-37</sub> (10 µM) group markedly reduced the necrosis rate of acinar cells (Supporting Information, Figure S1A,B).

To evaluate the potential therapeutic effect of NINJ1<sub>26-37</sub> on SAP in vivo, a classic SAP model was established by administering STC. Histological scoring demonstrated a significant increase in tissue, necrosis, inflammation, and edema in the SAP group, along with elevated amylase and lipase serum levels (Supporting Information, Figure S1C–E). Subsequent treatment with  $\text{NINJ1}_{26-37}$  significantly attenuated tissue necrosis and inflammatory infiltration and resulted in decreased levels of serum amylase and lactate dehydrogenase (LDH) compared to the STC group (Supporting Information, Figure S1E).

Additionally, immunofluorescence staining was performed on mouse pancreas samples to investigate the precise localization of NINJ1 expression and the impact of NINJ1 $_{26-37}$ interventions. The results revealed the expression of NINJ1 on the acinar cell membrane, which was significantly upregulated in the STC group. Treatment with  $NINJ1_{26-37}$  suppressed NINJ1 expression and oligomerization in SAP pancreatic acinar cells (Figure [1C](#page-2-0),D).

Taken together, our in vitro and in vivo experiments collectively demonstrate that NINJ1 is expressed on the acinar cell membrane and its expression is significantly upregulated in STC-SAP acinar cells. Moreover, the inhibition of NINJ1 expression by NINJ1 $_{26-37}$ 

could alleviate SAP, suggesting that targeting NINJ1 could be a promising therapeutic strategy for this disease.

The 266-6 mouse pancreatic cell lines were employed, and the suitable concentrations for STC-SAP modeling (1.5 mM) and NINJ1<sub>26-37</sub> administration (35  $\mu$ M) were determined through CCK-8 assays (Figure S2). Based on the aforementioned concentration, we conducted real-time imaging for 600 min using high-content screening (HCS) to observe cell morphology. We found that the 266-6 acinar cells in the control group did not rupture and produce new cells (Supporting Video S1). In the STC group, the acinar cells began to rupture at around 600 min. (Supporting Video S2). In the NINJ126-37 group, the acinar cells did not undergo rupture within 600 min (Figure [1E](#page-2-0), Supporting Video S3). An analysis of the cell perimeters showed no statistical difference between the control group, the STC group, and the NINJ1<sub>26-37</sub> group in the 0–300 min time period (Figure [1F](#page-2-0), Supporting Information Figure S3A). In the 300–600 min time period, the cell perimeter of the STC group was significantly larger compared to the control group (Figure [1F](#page-2-0), Supporting Information Figure S3B). The cell perimeter in the  $NINJ1_{26-37}$  group exhibited a significant increase compared to the STC group.

# *2.2. NINJ1 Knockout Inhibits PMR of Acinar Cells and Ameliorated SAP*

To further confirm the role of NINJ1 in SAP, NINJ1<sup>-/-</sup> mice were generated (Figure [2A](#page-4-0),B). Primary acinar cells from WT and NINJ1<sup>-/-</sup> mice were co-incubated with the STC separately in an experiment to induce acinar cells. There was no significant difference in necrosis rate between the NINJ1<sup>-/-</sup>-CON group and the WT-CON group. Furthermore, following treatment with STC, the NINJ1<sup>- $\bar{7}$ </sup>-STC group exhibited a significantly lower necrosis rate compared to the WT-STC group (Figure [2C](#page-4-0),D), suggesting that NINJ1<sup>-/-</sup> acinar cells have a protective effect against STC-induced cell death.

We conducted an HCS real-time imaging of the plasma membrane in primary acinar cells from NINJ1<sup>-/-</sup> mice over a 900 min duration. The NINJ1<sup>-/-</sup> group exhibited a significant decrease in PMR under STC treatment compared to the WT group (Figure [2E](#page-4-0), Supporting Videos S4–S7). Concurrently, we observed a significant increase in cell perimeter in the NINJ1<sup>-/-</sup> group compared to the WT group and in the NINJ1<sup>-/-</sup>-STC group compared to the NINJ1−/−-CON group during the 300–600 and 600–900 min intervals (Figure S4A–D). These findings suggest that NINJ1<sup>-/-</sup> can effectively delay the onset of PMR. Concurrently, we observed a significant increase in cell perimeter in the NINJ1<sup> $-$ / $-$ </sup> group compared to the WT group and in the NINJ1<sup>-/-</sup>-STC group compared to the NINJ1<sup>-/-</sup>-CON group during the 300–600 and 600–900 min intervals (Figure S4A–D). These findings suggest that NINJ1<sup>-/-</sup> can effectively delay the onset of PMR.

## *2.3. NINJ1 Expression Is Mediated by Ca2+*

Metal ions play a critical role in cells' physiological and pathological processes, and their dysfunction may ultimately contribute to PMR [\[26,](#page-16-14)[27\]](#page-16-15). To investigate the association between metal ions and NINJ1 in acinar cells, we conducted experiments where primary mouse acinar cells were incubated with calcium, potassium, magnesium, and sodium. Subsequently, proteins extracted via Western blot analysis revealed a notable upregulation of NINJ1 expression in cells incubated with  $Ca^{2+}$  (Figure [3A](#page-5-0),B). To further validate the influence of  $Ca^{2+}$  on NINJ1, we employed the  $Ca^{2+}$  chelator BAPTA-AM to modulate NINJ1 expression. As anticipated, the presence of BAPTA-AM led to a substantial reduction in NINJ1 protein expression (Figure [3C](#page-5-0),D). Nevertheless, BAPTA-AM has limited clinical applicability due to its inadequate targeting, prompting us to investigate a  $Ca^{2+}$  channel antagonist, AML, commonly employed for hypertension [\[28\]](#page-16-16). Previous studies have reported that AML can inhibit NINJ1 expression in human endothelial cells [\[23\]](#page-16-11). Given the crucial role of  $Ca^{2+}$  in the pathological mechanism of SAP, we hypothesized that AML may be effective against SAP.

<span id="page-4-0"></span>

**Figure 2.** Protective effect of NINJ1<sup>−/−</sup> on acinar cells. (**A**) NINJ1 DNA expression in acinar cells from NINJ1<sup>−/−</sup> mice. (**B**) Western blot detected NINJ1 protein expression in the NINJ1<sup>−/−</sup> mice acinar cells. GAPDH was used as the loading control  $(n = 3)$ . (C) Representative fluorescence plot of PI/Hoechst 33,342 staining in primary mouse acinar cells. Scale bar = 200 μm. (**D**) PI/Hoechst 33,342 staining necrosis bar chart of primary mouse acinar cells (*n* = 3). Data are presented as mean ± SEM, \*\* *p* < 0.01 indicates WT-CON vs. WT-STC, <sup>#</sup> *p* < 0.05 indicates WT-STC vs. KO-STC;  $\frac{1}{\sqrt{2}}$  and  $\frac{1}{\sqrt{2}}$  and ^ *p* < 0.05 indicates WT-STC vs. NINJ1<sup>-/-</sup>-STC. n.s = no significance. (**E**) HCS real-time imaging of mouse pancreatic acinar cell and representative pictures were selected from the periods of 300, 600, and 900 min in WT-CON group, WT-STC group, NINJ1−/−-CON group, NINJ1−/−-STC group (*n* = 3). STC: sodium taurocholate. HCS: high-content screening. Scale bar = 50 µm.

<span id="page-5-0"></span>

Figure 3. NINJ1 expression is mediated by Ca<sup>2+</sup> concentration. (A) Primary mouse acinar cells were incubated with different metal ions for 50 min, and the proteins were extracted for Western blot incubated with different metal ions for 50 min, and the proteins were extracted for Western blot experiments to detect the effects of  $\frac{2}{\sqrt{2}}$ ,  $\$ experiments to detect the effects of  $Ca^{2+}$ , K<sup>+</sup>, Mg<sup>2+</sup>, and Na<sup>+</sup> on NINJ1. (**B**) The quantitative plot of NINJ1 protein levels (*n* = 3). (**C**) Ca<sup>2+</sup> (10 mM) was added with mouse primary acinar cells and incubated with BAPTA-AM for 50 min, and the protein was extracted for Western blot analysis to detect the effect of BAPTA-AM on NINJ1. (**D**) The quantitative map of NINJ1 protein level ( $n = 3$ ). (E) Primary mouse acinar cells were incubated with AML (5 and 15  $\mu$ M) and incubated with STC (5 mM) for 50 min. Representative fluorescence plot of PI/Hoechst 33342 staining in primary mouse acing (*n* = 5). acinar cells. Scale bar = 200 μm. (**F**) Column of PI/Hoechst 33342 staining necrosis in primary mouse acinar cells (*n* = 5). (**G**) Primary mouse acinar cells were incubated with AML (15  $\mu$ M) combined with STC (5 mM) for 50 min, and the proteins were extracted for Western blot experiments. (H) The quantitative lot of NINJ1 protein levels (*n* = 3). STC: sodium taurocholate; AML: amlodipine. All data are presented as mean  $\pm$  SEM, \* *p* < 0.05, \*\*\* *p* < 0.001, \*\*\*\* *p* < 0.0001 vs. the control group.  $\frac{p}{p}$  < 0.05,  $\#$  *p* < 0.01,  $\#$  *p* + 0.0001,  $\hat{p}$  *p* < 0.01 vs. the STC group.

To examine this hypothesis, we performed in vitro experiments and discovered that AML at a concentration of 15  $\mu$ M effectively suppressed acinar cell necrosis (Figure [3E](#page-5-0),F) and attenuated NINJ1 expression (Figure [3G](#page-5-0),H). These findings indicate that the expression of NINJ1 is regulated by the  $Ca^{2+}$  level. Furthermore, AML demonstrated an effective inhibition of NINJ1 expression and a reduction in acinar cell necrosis, thereby suggesting the potential therapeutic utility of AML in the treatment of SAP.

#### *2.4. NINJ1 Inhibition by AML Improves SAP in Mice*

To further validate the effectiveness of AML in SAP, we administered AML (6 mg/kg) to mice with STC-induced SAP. An evaluation of histological scores revealed that AML attenuated pancreatic edema, inflammation, and necrosis in pancreatic tissue (Figure [4A](#page-7-0),B). Additionally, the AML group exhibited significant reductions in LDH, lipase, and amylase levels (Figure [4C](#page-7-0)). Furthermore, the immunofluorescence assay provided additional evidence of the significant inhibitory effect of AML on NINJ1 expression (Figure [4D](#page-7-0),E). These results demonstrate the substantial protective effects of AML against SAP and its significant inhibitory effect on NINJ1 expression.

# *2.5. Inhibition of Ca2+Channels Protects* ∆Ψ*m and Decreases P53 Expression*

To investigate the impact of AML on the  $Ca^{2+}$  levels, we initially utilized Fluo-4 AM, a  $Ca<sup>2+</sup>$  probe, to assess the cytoplasmic  $Ca<sup>2+</sup>$  levels. The STC group exhibited a significant increase in  $Ca^{2+}$  levels, while the AML group showed a decrease in intracellular  $Ca^{2+}$ concentration (Figure [5A](#page-8-0),B). Furthermore, we employed TMRM, a probe for measuring ∆Ψm, to assess changes in ∆Ψm. The STC group exhibited a reduction in ∆Ψm compared to the control group, whereas the AML group showed higher ∆Ψm levels than the STC group (Figure [5C](#page-8-0),D). Moreover, DCFH-DA, a probe for ROS, was utilized to monitor the ROS changes in each group. The level of ROS was significantly higher in the STC group compared with the control group, while it was significantly lower in the AML group (Figure [5E](#page-8-0),F). Additionally, we measured ROS indicators superoxide dismutase (SOD) and malondialdehyde (MDA). The experimental results showed decreased levels of SOD and increased levels of MDA in the STC group. AML increased SOD and reduced MDA levels in SAP acinar cells (Supporting Information, Figure S3). Furthermore, we observed that the expression of P53 was upregulated in the STC group and downregulated after treatment with AML (Figure [5G](#page-8-0),H). Collectively, STC can induce  $Ca^{2+}$  overload in acinar cells. This overload induces the loss of ∆Ψm, which disrupts the mitochondrial respiratory chain, promotes ROS overproduction, and upregulates P53 expression. AML decreases cytosolic  $Ca<sup>2+</sup>$  levels, thereby mitigating mitochondrial damage and downregulating P53 expression.

# *2.6. P53 Upregulates NINJ1 to Induce PMR*

P53, as a transcriptional factor, binds to the promoter of NINJ1 to enhance its expression in MCF7 cells, and NINJ1 could promote PMR [\[11](#page-16-0)[,21\]](#page-16-9). To further confirm the involvement of P53 in regulating NINJ1 expression in acinar cells, we incubated primary acinar cells with either P53 agonist RITA or inhibitor PFT-α. We conducted a necrosis examination on acinar cells to identify effective concentrations. Treatment with RITA at 10  $\mu$ M significantly promoted acinar cell necrosis, whereas  $PFT-\alpha$  at 40  $\mu$ M protected against acinar cell necrosis (Supporting Information, Figure S6A,B). Subsequently, the expression of P53 and NINJ1 was increased in acinar cells treated with RITA and decreased in those treated with PFT-α (Figure [6A](#page-9-0),B). These results indicate that P53 can regulate the expression of NINJ1 in primary acinar cells and may play a crucial role in the pathogenesis of PMR.

<span id="page-7-0"></span>

**Figure 4.** Effect of AML on pancreatic tissue in STC-SAP mice. (A) AML (6 mg/kg) was intraperitoneal injected once a day three times before modeling; SAP was induced by retrograde injection of 3.5% STC into the pancreaticobiliary duct. Samples were taken 24 h later. Scale bar = 50  $\mu$ m. (**B**) The histopathological score of mouse pancreas (*n* = 5). (**C**) Serum levels of lactate dehydrogenase, lipase, and amylase were measured (*n* = 3). (**D**) Immunofluorescence plot of NINJ1 on pancreatic tissue, Yellow square = enlarged area. White arrow = oligomerization. Scale bar = 100 µm. (**E**) The quantitative map of NINJ1 fluorescence levels (*n* = 5). STC: sodium taurocholate. SAP: severe acute pancreatitis. AML: amlodipine. All data are presented as mean ± SEM, \*\* *p* < 0.01, *\*\*\* p* < 0.001, \*\*\*\* *p* < 0.0001 vs. the control group,  $\# p$  < 0.05,  $\#$  *p* < 0.01,  $\#$  $\#$  *p* < 0.0001 vs. the STC group.

<span id="page-8-0"></span>

Figure 5. AML via inhibition of intracellular  $Ca^{2+}$  to inhibit ROS-P53. (A) Mouse primary acinar cells incubated with 15  $\mu$ M AML for 30 min; Fluo-4 AM was added for another 20 min; STC (5 mM)  $\frac{1}{\sqrt{2}}$ was added before microscopy, and then observed under confocal microscope. A representative  $\mathbb{R}^n$ Fluo-4 AM staining. Scale bar = 100 μm. (**B**) The quantitative plot of Fluo-4AM fluorescence levels  $(n = 3)$ . (**C**) Primary mouse acinar cells were incubated with 15  $\mu$ M AML for 30 min, followed by the addition of TMRM for another 20 min, and then observed under confocal microscope. The representative TMRM staining. Scale = 100 μm. (**D**) A quantitative map of TMRM fluorescence levels  $(n = 3)$ . (E) Primary mouse acinar cells were incubated with 15  $\mu$ M AML for 30 min; then, DCFH-DA was added and co-incubated for another 20 min before observation under confocal microscope. The representative DCFH-DA staining. Scale = 100 μm. (**F**) The quantitative plot of DCFH-DA fluorescence levels ( $n = 3$ ). (**G**) The primary mouse acinar cells were incubated with AML and STC tative plot of P53 protein levels (*n* = 4). AML: amlodipine, STC: sodium taurocholate. All data are for 50 min, and the protein was extracted for Western blot analysis to detect the effect of AML on P53. (**H**) The quantitative plot of P53 protein levels (*n* = 4). AML: amlodipine, STC: sodium taurocholate. All data are presented as mean  $\pm$  SEM, \*\*  $p < 0.01$  vs. the control group;  $\# p < 0.05$  vs. the STC group.

<span id="page-9-0"></span>

Figure 6. NINJ1 is regulated by P53 and affects PMR. (A) Primary mouse acinar cells were incubated  $\frac{1}{2}$  STC, RITA, and PFT- $\frac{a}{a} = 50$  min. The effects of STC on P53 and NINJ1 were detected by Westwith STC, RITA, and PFT-α for 50 min. The effects of STC on P53 and NINJ1 were detected by<br>with STC, RITA, and PFT-α for 50 min. The effects of STC on P53 and NINJ1 were detected by Western blot. (**B**) The quantitative plot of P53 ( $n = 4$ ) and NINJ1 ( $n = 5$ ) protein levels. (**C**) 266-6 mouse pancreatic acinar cells were captured by HCS real-time imaging. Scale bar = 50 µm (**D**) An HCS data analysis system was used to analyze the changes in cell perimeter at different time points. STC: sodium taurocholate; RITA: P53 agonist; PFT-α: P53 inhibitor. HCS: high-content screening. PMR: plasma membrane rupture. All data are presented as mean ± SEM, \*\* *p* < 0.01, \*\*\* *p* < 0.001 vs. the control group,  $^{#}p$  < 0.05,  $^{#}p$  < 0.05, ^ $p$  < 0.05, ^ $p$  < 0.05 vs. the STC group.

To further demonstrate the regulatory role of P53 in mediating PMR via NINJ1, a CCK-8 assay was used to screen appropriate RITA (3  $\mu$ M) and PFT- $\alpha$  (10  $\mu$ M) concentrations for 266-6 (Supporting Information, Figure S2C,D). According to HCS real-time imaging for 600 min, the cell perimeter of the STC group was significantly larger than that of the control group. The perimeter of the PFT- $\alpha$  group increased considerably at 100 min and started to decrease at 300 min, and it eventually returned to the level of the control group at 600 min. The cell perimeter of the RITA group was smaller than that of the STC group for the first 300 min, and it increased significantly between 300 and 600 min, exceeding 70  $\mu$ m at 600 min (Figure [6C](#page-9-0),D, Supporting Information Figure S7A,B, Supporting Video S8–S11). These results suggest that inhibiting NINJ1 could promote the maintenance of a larger cell membrane perimeter to prevent rupture. When P53 was upregulated, the cell perimeter was smaller than the STC group during the first 300 min and directly increased to 70  $\mu$ m during the last 300 min. It is possible that NINJ1 activation caused cell membrane rupture, leading to the induction of DAMPs, extensive cell rupture, and an increased cell perimeter. In conclusion, P53 plays a role in regulating NINJ1 expression and mediating PMR in SAP acinar cells.

# **3. Discussion**

SAP is an inflammatory disease of the pancreas characterized by tissue damage, PMR, and the necrosis of acinar cells. It is also referred to as necrotizing pancreatitis due to

its features [\[29\]](#page-16-17). Currently, there is no effective pharmacological treatment to halt the progression of the disease. Therefore, it is necessary to identify new protein targets.

This article aimed to validate the expression and function of NINJ1 in pancreatic acinar cells. Initially, we observed the upregulation of NINJ1 in primary acinar cells upon STC stimulation. To investigate the impact of NINJ1 on acinar cells, we employed NINJ126-37, which primarily diminishes immune cell recruitment by targeting the adhesive domain of NINJ1 [\[24\]](#page-16-12). Previously, our group study demonstrated that NINJ1<sub>26-37</sub> diminishes platelet PMR, thereby suppressing adhesion and aggregation [\[25\]](#page-16-13). To verify the involvement of NINJ1 in SAP, we conducted in vitro and in vivo experiments, demonstrating the therapeutic effect of NINJ126-37 on SAP. However, whether NINJ1 regulates PMR in acinar cells remains unknown. Consequently, we employed HCS real-time imaging to analyze morphological alterations. Our findings showed that the cell perimeter of 266-6 co-treated with STC and NINJ1 $_{26-37}$  was larger than that of the STC group. This indicates that NINJ1 $_{26-37}$ could promote the perimeter of acinar cells to reduce PMR by inhibiting NINJ1. The aforementioned experiments provided evidence that NINJ1 inhibition can reduce PMR and alleviate SAP both in vivo and in vitro.

In order to further ascertain the role of NINJ1, we generated NINJ1<sup>-/-</sup> mice and conducted in vitro experiments to validate its impact on SAP. HCS real-time imaging demonstrated increased cell perimeters compared to the WT group. Moreover, STC treatment led to a significantly prolonged PMR duration in primary acinar cells from NINJ1−/<sup>−</sup> mice. Based on the findings from necrosis experiments, we can infer that NINJ1 depletion may delay the onset of PMR and mitigate SAP.

We observed a notable upregulation of NINJ1 expression in STC-SAP acinar cells. Current research indicates that STC triggers a pathological elevation of intracellular Ca<sup>2+</sup>, inducing acinar cell PMR. Thus, we hypothesize that NINJ1 expression might be related to the changes in intracellular  $Ca^{2+}$  levels. To validate this hypothesis, we co-cultured acinar cells with various metal ions and observed a significant elevation in NINJ1 expression upon  $Ca<sup>2+</sup>$  treatment, which subsequently decreased following BAPTA-AM treatment.

AML, as a dihydropyridine  $Ca^{2+}$  channel blocker, has the potential to decrease the expression of NINJ1 through the inhibition of ROS and NF-κB induced by ER stress [\[23\]](#page-16-11). However, the precise mechanism underlying AML's inhibition of ROS and ER stress remains unexplored [\[23\]](#page-16-11). Our experiments demonstrated that AML provided relief from SAP both in vivo and in vitro. Furthermore, we observed that AML reduced cytoplasmic  $Ca^{2+}$  levels, which protected against mitochondrial dysfunction and the loss of  $\Delta \Psi$ m. This led to a decrease in ROS production and facilitated the expected degradation of P53, preventing acinar cell death. Nevertheless, AML is known to be a specific inhibitor of Ltype voltage-gated  $Ca^{2+}$  channels, which are clearly absent from pancreatic acinar cells [\[13\]](#page-16-2); therefore, the specific regulatory mechanism of AML in SAP will be the focus of our future research.

P53 elicits cellular repair or death, both of which can be attributed to mitochondrial dysfunction and oxidative stress [\[30,](#page-16-18)[31\]](#page-16-19). Apoptosis is widely acknowledged as the principal outcome associated with P53 activity. Intriguingly, emerging evidence has gradually suggested that P53 might induce necrosis in acinar cells affected by SAP [\[19,](#page-16-20)[20\]](#page-16-8), thus bestowing a novel perspective on P53. Apart from NINJ1, other mechanisms may also contribute to acinar cell necrosis. Our findings revealed that RITA (a P53 agonist) diminished the rate of acinar cell survival, whereas  $PFT-\alpha$ , a P53 inhibitor, resulted in an elevated survival rate in primary acinar cells and 266-6 cells. Lastly, HCS real-time imaging substantiated the inducement of PMR by RITA and the preventive effect of PFT-α against PMR. Consequently, these findings elucidate the involvement of P53 in mediating PMR through NINJ1 during SAP.

This study, for the first time, elucidated the expression of NINJ1 in pancreatic acinar cells and investigated its role in SAP. Furthermore, we discovered that the expression of NINJ1 is regulated by  $Ca^{2+}$  and demonstrated that  $Ca^{2+}$  is responsible for the upregulation of P53 through the induction of mitochondrial stress in acinar cells. Lastly, we delved deeper into the mechanism by which P53 regulates NINJ1 and identified its impact on the occurrence of PMR.

#### **4. Materials and Methods**

# *4.1. Animals*

The animal care and experimental procedures used in this article have been approved by the Ethics Committee of West China Hospital, Sichuan University (Chengdu, China), with a date of issue from March 2021 to March 2023, approval NO: 2021929A, and follow the Guide of Laboratory Animal Care and Use (Institute of Laboratory Animal Resources, 1996).

A total of 68 WT and 5 NINJ1<sup>-/-</sup> male C57BL/6 mice aged 6–10 weeks from Gem-Pharmatech (Shanghai, China) were used in this study. Approximately 4–5 mice were allocated to each cage and raised in the SPF level animal room of West China Hospital, Sichuan University (Chengdu, China). The temperature was maintained at 23–26 ◦C and the relative humidity was maintained at around 50%. The mice were able to freely obtain specialized feed and sterilized drinking water.

#### *4.2. Materials*

Sodium taurocholate and Collagenase IV were purchased from Sigma-Aldrich (St. Louis, MO, USA). Hoechst 33342 and propidium iodide were purchased from Yeasen (Shanghai, China).  $NINJ1_{26-37}$  (sequence: PPRWGLRNRPIN) and Scramble peptide (sequence: PPRAGLRNRPIN) were purchased from Bootai (Shanghai, China). RITA was purchased from APExBIO (Houston, TX, USA). PFT-α and tetramethylrhodamine methyl ester (TMRM) were purchased from MCE (Monmouth Junction, NJ, USA). Amlodipine (AML) and BAPTA-AM were purchased by Aladdin (Shanghai, China). Protease inhibitor, RIPA, DCFH-DA, Fluo-4 AM streptomycin, and penicillin were purchased from Beyotime (Shanghai, China). Superoxide dismutase (SOD) and malondialdehyde (MDA) were purchased from Solarbio (Beijing, China). Bicinchoninic acid (BCA) protein assay kit, Cell Counting Kit-8 (CCK8), and RIPA lysis buffer were purchased from Meilunbio (Dalian, China). Dulbecco's Modified Eagle Medium (DMEM) and fetal bovine serum were purchased from GIBCO (Grand Island, NY, USA). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) of Merck. LDH assay kits were purchased from Jiancheng (Nanjing, China). Anti-NINJ1 and secondary antibodies were purchased from Bioss (Beijing, China). NINJ1 and MCU antibodies were purchased from Abclonal (Wuhan, China); IP3R antibody was obtained from Santa Cruz Biotechnology (Santa Cru, CA, USA); P53 antibody was purchased from Abcam (Cambridge, UK).

#### *4.3. Animal Model of SAP and Treatments*

Twenty wild-type C57BL/6 mice were randomly divided into four groups, including a control group, STC group, STC + NINJ1<sub>26-37</sub> (3 mg/kg) group, and STC + NINJ1<sub>26-37</sub> (6 mg/kg) group [\[32\]](#page-16-21). The other twenty wild-type C57BL/6 mice were randomly divided into four groups, including a control group, STC group, STC + AML (3 mg/kg) group, and STC + AML (6 mg/kg) group [\[33,](#page-16-22)[34\]](#page-16-23).

 $NINJ1_{26-37}$  or AML was dissolved in physiological saline to prepare a 2 mg/mL  $NINJ1_{26-37}$  or AML solution. The solution was solubilized under ultrasound and used immediately after preparation. Two days before and after retrograde injection of the pancreatobiliary duct, a daily dose of 3 mg/kg (50  $\mu$ L) and 6 mg/kg (100  $\mu$ L) of NINJ1<sub>26-37</sub> or AML was administrated to different groups through intraperitoneal injection. For the control group and the STC group, the same volume of physiological saline solution was applied  $(100 \mu L)$ .

The previously described method was used [\[35\]](#page-16-24); the mice were fasted for 12 h but had access to water before the surgery. A 3.5% STC physiological saline solution was prepared and warmed to 37 °C before use. Then, the mice were weighed and labeled. An intraperitoneal injection of tribromoethanol (2.5%, 100–150 µL per mouse) was administered

before waiting for the mice to gradually lose consciousness, ensuring no response when pressing their paws.

Using a shaving razor, the abdominal fur was removed from the mice. The mice were secured on a sterile surgical table. Iodine solution was applied to the surgical site for disinfection. Using fine surgical instruments, a midline incision was made through the skin and muscle layers of the abdomen. The duodenum was located and the pancreatic ducts, bile ducts, and duodenal papilla were exposed. Throughout the procedure, moisture was maintained in the abdominal cavity by adding the necessary amount of physiological saline.

The path of the bile duct was traced upwards from beneath the liver, and an arterial clamp was used to secure it. The duodenum was flattened and the syringe was inserted through it, entering the pancreatic duct via the duodenal papilla. The solution was slowly injected into the pancreas using a microinfusion pump at a rate of  $5 \mu L/min$ . The injection volume was 0.1 mL/100 g for each mouse. In the control group, the same volume of physiological saline solution was injected. After completing the injection, the clamp was removed and the muscle and skin layers were sutured. The area with was disinfected with iodine solution and the mice were positioned on a heating pad to maintain body temperature while monitoring their physiological condition.

Prior to sampling, after 24 h of modeling, the mice were anesthetized using an appropriate volume of tribromoethanol. The mice were secured on a sterile operating table and an upper abdominal incision was made to fully expose the thoracic cavity and heart. The needle tip of the syringe was inserted into the mouse's cardiac apex for blood extraction. The collected blood was transferred into a sterile 1.5 mL EP tube and left to stand at room temperature for 30 min prior to centrifugation. This was used for the subsequent detection of lipase and amylase. The pancreatic tissue was collected for H&E staining and IF.

#### *4.4. Histopathology*

The pathological changes in pancreatic tissue were analyzed. Fresh pancreases were soaked in 4% paraformaldehyde for 48 h. Pancreas tissue was embedded in paraffin and cut into 3  $\mu$ m pieces. Each slice was colored with H&E. The sample was observed under a microscope and the pancreas pathological changes at  $200 \times$  magnification were evaluated. The concealed evaluation of pancreatic histopathological scores was performed by two pathologists: the score range for necrosis, inflammatory cell infiltration, and edema were all in the range 0–3.

#### *4.5. Immunofluorescence Staining*

Pancreatic paraffin sections  $(3 \mu m)$  were prepared and blocked with blank goat serum in PBST to 5%, followed by overnight incubation at 4 ◦C with anti-NINJ1 antibodies (1:100 dilution). The slices were then incubated with secondary antibodies (1 h, 37  $\degree$ C). After cleaning with PBS, DAPI was used for nuclear staining (10 min, 37 ◦C) at a dilution of 1:2000. The stained sample was observed with a confocal microscope (Nikon A1plus, Tokyo, Japan) and measured at excitation and emission wavelengths of 640 nm and 700 nm. Finally, the fluorescence area was quantified using ImageJ (version 1.51k).

The isolated primary acinar cells were first exposed to STC for 50 min. They were soaked with 4% paraformaldehyde for 1 h, followed by incubation with anti-NINJ1 antibodies (dilution of 1:100) overnight at  $4 °C$ . Subsequently, the cells were incubated with the corresponding secondary antibodies in the dark for 1 h at 37 ◦C. Finally, DAPI was used to counterstain the cells for 10 min. The stained specimens were visualized with a confocal microscope (Nikon A1plus, Tokyo, Japan) and measured at excitation and emission wavelengths of 640 nm and 700 nm. Finally, the fluorescence area was quantified using ImageJ (version 1.51k).

# *4.6. Preparation of Pancreatic Acinar Cells*

The primary acinar cells used in the experiment were isolated from male C57BL/ 6 mice [\[36\]](#page-16-25). The pancreases of the mice were treated with collagenase IV (200 U/mL) at  $37 \text{ °C}$  for 20 min. The resulting cells were dissociated mechanically, filtered through a 100 µm cell filter, and centrifuged at 700 rpm for 2 min to collect the cell precipitates. The cells were then diluted by Hepes solution (140 mM NaCl, 4.7 mM KCl, 1.13 mM  $MgCl<sub>2</sub>$ , 1 mM CaCl2, 10 mM D-glucose, and 10 mM Hepes, adjusted to pH 7.35 with NaOH) and kept at  $37^{\circ}$ C.

## *4.7. STC-Induced Acinar Cell Death Measurement In Vitro*

The previously described method was used [\[37\]](#page-17-0). Primary acinar cells were treated with STC (5 mM) and incubated at 37 °C for 50 min with or without AML (5 and 15  $\mu$ M), NINJ1<sub>26-37</sub> (5 and 10  $\mu$ M), and Scramble peptide (5 and 10  $\mu$ M). The cells were then stained with propidium iodide (PI: 1  $\mu$ mol/mL) and Hoechst 33,342 (50  $\mu$ g/mL) to label the total number of nuclear and necrotic cells characterized by PMR. Images were captured using an Automatic ZEISS AX10 imager A2/AX10 cam HRC (Oberkochen, Germany). The total number of acinar cells demonstrating PI uptake was recorded for each condition to determine the percentage of necrosis, with five independent isolates used for each condition.

# *4.8. Detection of ROS*

The previously described method was used [\[38\]](#page-17-1); ROS levels in the acinar cells were measured using DCFH-DA (10 µM). DCFH-DA was added to primary acinar cells at 37  $^{\circ}$ C in the black container for 20 min before cells were washed twice with Hepes solution and subsequently treated with STC and AML for 50 min. The treated cells were placed on the glass slides, and the images were rapidly observed using a confocal microscope (Nikon A1plus, Tokyo, Japan) with excitation at 488 nm and emission at 525 nm. The fluorescence intensity was then analyzed using Image J (version 1.51k).

# *4.9.* ∆Ψ*m Measurement*

TMRM (1 µM) was used to evaluate ∆Ψm. The acinar cells were incubated with STC and AML for a specific duration before TMRM was added and cells were incubated in the dark at  $37 \text{ °C}$  for 20 min. After loading, the acinar cells were washed with Hepes solution twice and placed under a confocal microscope (Nikon A1plus, Tokyo, Japan) with excitation at 561 nm and emission at 595 nm. The fluorescence intensity was quantified using Image J (version 1.51k).

# *4.10. Detection of Intracellular Calcium Content*

To measure  $Ca^{2+}$  content in the cytoplasm, the Fluo-4 AM probe was used. The isolated primary acinar cells diluted in Hepes solution without  $Ca<sup>2+</sup>$  were co-incubated with AML (10  $\mu$ M) and Fluo-4 AM stain for 30 min. After staining, the cells were suspended twice and rapidly observed under a confocal microscope (Nikon A1plus, Tokyo, Japan) with the addition of STC (5 mM). The fluorescence was pictured with excitation at 488 nm and emission at 525 nm. The fluorescence intensity was quantified using Image J (version 1.51k).

# *4.11. Detection of Serum Amylase and Lipase*

Blood samples were centrifuged at 3000 rpm for 10 min, and 40 µL blood serum was diluted to 200  $\mu$ L with pure water. The serum lipase and amylase were measured by an automatic biochemical analyzer (Roche, Mannheim, Germany).

#### *4.12. Western Blot Analysis*

As previously mentioned [\[37\]](#page-17-0), protein lysates from acinar cells were prepared using RIPA buffer (RIPA:PMSF = 100:1). A total of 20  $\mu$ g of protein lysate samples was loaded onto a polyacrylamide gel and separated by electrophoresis. The separated proteins were transferred from the gel to a PVDF membrane using a wet transfer method. Subsequently, the PVDF membrane was blocked with a blocking solution containing milk to prevent the non-specific binding of antibodies. The membrane was incubated with primary antibodies (1:1000) specific to the target proteins, followed by incubation with secondary antibodies (1:10,000) conjugated to enzymes after washing and containing 1% Tween. The protein bands were visualized using chemiluminescent or chromogenic substrates that reacted with the enzymes conjugated to the secondary antibodies. Finally, the membrane was exposed using an imaging system, such as the Bio-Rad CHEMIDOC MP (Hercules, CA, USA), to capture the protein bands. The relative protein expression levels were quantified using Bio-Rad Image Lab 3.0 software (Hercules, CA, USA), standardized based on the protein expression levels of GAPDH, and compared to the normalized protein levels of the control cells. The control protein level was set to 1.0 for comparison, and the results represent three independent experiments.

## *4.13. Cell Culture*

The 266-6 cell line from mouse pancreatic acinar cells was obtained from the Department of Integrated Traditional Chinese and Western Medicine at West China Hospital and was cultured in DMEM containing 10% fetal bovine serum and 100  $\mu$ g/mL streptomycin and penicillin in an incubator maintained at 37 °C with 5%  $CO<sub>2</sub>$ .

## *4.14. Cell Viability Assay*

The CCK-8 assay was performed for cell viability. The cells were treated with different concentrations of NINJ1<sub>26-37</sub> (15, 20, 25, 30, and 35  $\mu$ M), RITA (3, 6, 9, 12, and 15  $\mu$ M), and PFT- $\alpha$  (3, 6, 9, 12, and 15 μM) with STC (1.5 mM) for 24 h. At the endpoint, 10 μL of CCK-8 was added to every well and incubated for 4 h. Biotex Synergy Mx microplate reader (EL Segundo, CA, USA) was used for measurements at 450 nm absorbance.

#### *4.15. HCS Real-Time Imaging*

Primary acinar cells and 266-6 cells were used with Perkin Elmer CellCarrier-96 Ultra (Waltham, MA, USA). Cell carriers were imaged using a  $40\times$  or  $10\times$  Air objective on Perkin Elmer Opera Phenix Plus HCS System (Waltham, MA, USA) equipped with an environmental controller and gas mixer to maintain cells at  $37^{\circ}$ C and  $5\%$  CO<sub>2</sub>. The bright field was imaged every 5 min overnight. Images were processed and videos were generated using Perkin Elmer Harmony<sup>®</sup> (Waltham, MA, USA). The outcome analysis was processed in Perkin Elmer Harmony® (Waltham, MA, USA) using a custom script with a graphic user interface representing data at the field and plate levels.

#### *4.16. Statistical Analysis*

The data were calculated as the mean  $\pm$  SEM. One-way ANOVA was used, followed by Dunnett's post hoc test. Statistical analysis was presented using GraphPad Prism 8.0 (San Diego, CA, USA). The results were calculated using data from at least three independent experiments. *p* < 0.05 was considered statistically significant.

**Supplementary Materials:** The following supporting information can be downloaded at [https:](https://www.mdpi.com/article/10.3390/ijms241411554/s1) [//www.mdpi.com/article/10.3390/ijms241411554/s1.](https://www.mdpi.com/article/10.3390/ijms241411554/s1)

**Author Contributions:** The experimental design was conceived by C.L., G.X. and W.H.; The experiments were performed by C.L., F.L., C.W., X.Y., L.F. and A.W.; The statistical analysis was conducted by C.L., G.X. and Y.C.; C.L. wrote the manuscript, which was later revised by G.X., W.H. and Y.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** The 1·3·5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYXY21002); The Innovative Chinese Medicine Preclinical Research Fund of "Liqing No. 2", West China Hospital, Sichuan University (161200012); Innovative Chinese Medicine and Health Products Research Academician Workstation of Academician Boli Zhang and Academician Beiwei Zhu, West China Hospital, Sichuan University (HXYS19001, HXYS19002); Key R&D project of Science and Technology Department of Sichuan Province (Grant No. 2022YFS0335); The Sichuan Province COVID-19 Science and Technology Emergency Project (2021YFS0408); The National Natural Science Foundation of China (Grant No.81973580, 81803866); The Key Technology Research and Development Program of Sichuan Province of China (2022YFS0425,2022YFS0426).

**Institutional Review Board Statement:** Animal experiments and methods were authorized by the Ethics Committee of West China Hospital, Sichuan University (Ethics record number: 2021929A).

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** This article and Supplementary Material contains all data from this study.

**Conflicts of Interest:** There are no conflict of interest in this article.

# **Abbreviations**



# **References**

- <span id="page-15-0"></span>1. Hines, O.J.; Pandol, S.J. Management of severe acute pancreatitis. *BMJ* **2019**, *367*, l6227. [\[CrossRef\]](https://doi.org/10.1136/bmj.l6227)
- <span id="page-15-1"></span>2. Boxhoorn, L.; Voermans, R.P.; Bouwense, S.A.; Bruno, M.J.; Verdonk, R.C.; Boermeester, M.A.; van Santvoort, H.C.; Besselink, M.G. Acute pancreatitis. *Lancet* **2020**, *396*, 726–734. [\[CrossRef\]](https://doi.org/10.1016/S0140-6736(20)31310-6)
- <span id="page-15-2"></span>3. Banks, P.A.; Bollen, T.L.; Dervenis, C.; Gooszen, H.G.; Johnson, C.D.; Sarr, M.G.; Tsiotos, G.G.; Vege, S.S. Classification of acute pancreatitis--2012: Revision of the Atlanta classification and definitions by international consensus. *Gut* **2013**, *62*, 102–111. [\[CrossRef\]](https://doi.org/10.1136/gutjnl-2012-302779)
- <span id="page-15-3"></span>4. Iannuzzi, J.P.; King, J.A.; Leong, J.H.; Quan, J.; Windsor, J.W.; Tanyingoh, D.; Coward, S.; Forbes, N.; Heitman, S.J.; Shaheen, A.-A. Global incidence of acute pancreatitis is increasing over time: A systematic review and meta-analysis. *Gastroenterology* **2022**, *162*, 122–134. [\[CrossRef\]](https://doi.org/10.1053/j.gastro.2021.09.043)
- <span id="page-15-4"></span>5. Xiao, A.Y.; Tan, M.L.Y.; Wu, L.M.; Asrani, V.M.; Windsor, J.A.; Yadav, D.; Petrov, M.S. Global incidence and mortality of pancreatic diseases: A systematic review, meta-analysis, and meta-regression of population-based cohort studies. *Lancet Gastroenterol. Hepatol.* **2016**, *1*, 45–55. [\[CrossRef\]](https://doi.org/10.1016/S2468-1253(16)30004-8)
- <span id="page-15-5"></span>6. Pagliari, D.; Brizi, M.G.; Saviano, A.; Mancarella, F.A.; Dal Lago, A.A.; Serricchio, M.L.; Newton, E.E.; Attili, F.; Manfredi, R.; Gasbarrini, A. Clinical assessment and management of severe acute pancreatitis: A multi-disciplinary approach in the XXI century. *Eur. Rev. Med. Pharmacol. Sci.* **2019**, *23*, 771–787. [\[CrossRef\]](https://doi.org/10.26355/eurrev_201901_16892)
- <span id="page-15-6"></span>7. Jabłońska, B.; Mrowiec, S. Nutritional support in patients with severe acute pancreatitis-current standards. Nutrients 2021, *13*, 1498. [\[CrossRef\]](https://doi.org/10.3390/nu13051498)
- <span id="page-15-7"></span>8. Lee, P.J.; Papachristou, G.I. New insights into acute pancreatitis. *Nat. Rev. Gastroenterol. Hepatol.* **2019**, *16*, 479–496. [\[CrossRef\]](https://doi.org/10.1038/s41575-019-0158-2)
- <span id="page-15-8"></span>9. Leppäniemi, A.; Tolonen, M.; Tarasconi, A.; Segovia-Lohse, H.; Gamberini, E.; Kirkpatrick, A.W.; Ball, C.G.; Parry, N.; Sartelli, M.; Wolbrink, D.; et al. 2019 WSES guidelines for the management of severe acute pancreatitis. *World J. Emerg. Surg.* **2019**, *14*, 27. [\[CrossRef\]](https://doi.org/10.1186/s13017-019-0247-0)
- <span id="page-15-9"></span>10. Araki, T.; Milbrandt, J. Ninjurin, a novel adhesion molecule, is induced by nerve injury and promotes axonal growth. *Neuron* **1996**, *17*, 353–361. [\[CrossRef\]](https://doi.org/10.1016/S0896-6273(00)80166-X)
- <span id="page-16-0"></span>11. Lee, H.J.; Ahn, B.J.; Shin, M.W.; Choi, J.-H.; Kim, K.-W. Ninjurin1: A potential adhesion molecule and its role in inflammation and tissue remodeling. *Mol. Cells* **2010**, *29*, 223–227. [\[CrossRef\]](https://doi.org/10.1007/s10059-010-0043-x) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/20119872)
- <span id="page-16-1"></span>12. Kayagaki, N.; Kornfeld, O.S.; Lee, B.L.; Stowe, I.B.; O'Rourke, K.; Li, Q.; Sandoval, W.; Yan, D.; Kang, J.; Xu, M.; et al. NINJ1 mediates plasma membrane rupture during lytic cell death. *Nature* **2021**, *591*, 131–136. [\[CrossRef\]](https://doi.org/10.1038/s41586-021-03218-7) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/33472215)
- <span id="page-16-2"></span>13. Petersen, O.H.; Gerasimenko, J.V.; Gerasimenko, O.V.; Gryshchenko, O.; Peng, S. The roles of calcium and ATP in the physiology and pathology of the exocrine pancreas. *Physiol. Rev.* **2021**, *101*, 1691–1744. [\[CrossRef\]](https://doi.org/10.1152/physrev.00003.2021) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/33949875)
- <span id="page-16-3"></span>14. Biczo, G.; Vegh, E.T.; Shalbueva, N.; Mareninova, O.A.; Elperin, J.; Lotshaw, E.; Gretler, S.; Lugea, A.; Malla, S.R.; Dawson, D.; et al. Mitochondrial dysfunction, through impaired autophagy, leads to endoplasmic reticulum stress, deregulated lipid metabolism, and pancreatitis in animal models. *Gastroenterology* **2018**, *154*, 689–703. [\[CrossRef\]](https://doi.org/10.1053/j.gastro.2017.10.012)
- <span id="page-16-4"></span>15. Criddle, D.N.; McLaughlin, E.; Murphy, J.A.; Petersen, O.H.; Sutton, R. The pancreas misled: Signals to pancreatitis. *Pancreatology* **2007**, *7*, 436–446.
- <span id="page-16-5"></span>16. Marolt, U.; Paradiž Leitgeb, E.; Pohorec, V.; Lipovšek, S.; Venglovecz, V.; Gál, E.; Ébert, A.; Menyhárt, I.; Potrč, S.; Gosak, M.; et al. Calcium imaging in intact mouse acinar cells in acute pancreas tissue slices. *PLoS ONE* **2022**, *17*, e0268644. [\[CrossRef\]](https://doi.org/10.1371/journal.pone.0268644)
- <span id="page-16-6"></span>17. Niwa-Kawakita, M.; Ferhi, O.; Soilihi, H.; Le Bras, M.; Lallemand-Breitenbach, V.; de Thé, H. PML is a ROS sensor activating p53 upon oxidative stress. *J. Exp. Med.* **2017**, *214*, 3197–3206. [\[CrossRef\]](https://doi.org/10.1084/jem.20160301)
- <span id="page-16-7"></span>18. Shi, T.; Dansen, T.B. Reactive oxygen species induced p53 activation: DNA damage, redox signaling, or Both? *Antioxid. Redox Signal.* **2020**, *33*, 839–859. [\[CrossRef\]](https://doi.org/10.1089/ars.2020.8074)
- <span id="page-16-20"></span>19. Rius-Pérez, S.; Pérez, S.; Toledano, M.B.; Sastre, J. P53 drives necroptosis via downregulation of sulfiredoxin and peroxiredoxin 3. *Redox Biol.* **2022**, *56*, 102423. [\[CrossRef\]](https://doi.org/10.1016/j.redox.2022.102423)
- <span id="page-16-8"></span>20. Napoletano, F.; Gibert, B.; Yacobi-Sharon, K.; Vincent, S.; Favrot, C.; Mehlen, P.; Girard, V.; Teil, M.; Chatelain, G.; Walter, L.; et al. P53-dependent programmed necrosis controls germ cell homeostasis during spermatogenesis. *PLoS Genet.* **2017**, *13*, e1007024. [\[CrossRef\]](https://doi.org/10.1371/journal.pgen.1007024)
- <span id="page-16-9"></span>21. Cho, S.-J.; Rossi, A.; Jung, Y.-S.; Yan, W.; Liu, G.; Zhang, J.; Zhang, M.; Chen, X. Ninjurin1, a target of p53, regulates p53 expression and p53-dependent cell survival, senescence, and radiation-induced mortality. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 9362–9367. [\[CrossRef\]](https://doi.org/10.1073/pnas.1221242110)
- <span id="page-16-10"></span>22. Li, Y.; Zhao, D.; Qian, M.; Liu, J.; Pan, C.; Zhang, X.; Duan, X.; Zhang, Y.; Jia, W.; Wang, L. Amlodipine, an anti-hypertensive drug, alleviates non-alcoholic fatty liver disease by modulating gut microbiota. *Br. J. Pharmacol.* **2022**, *179*, 2054–2077. [\[CrossRef\]](https://doi.org/10.1111/bph.15768)
- <span id="page-16-11"></span>23. Toma, L.; Sanda, G.M.; Raileanu, M.; Stancu, C.S.; Niculescu, L.S.; Sima, A.V. Ninjurin-1 upregulated by TNFα receptor 1 stimulates monocyte adhesion to human TNFα-activated endothelial cells; benefic effects of amlodipine. *Life Sci.* **2020**, *249*, 117518. [\[CrossRef\]](https://doi.org/10.1016/j.lfs.2020.117518) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/32147432)
- <span id="page-16-12"></span>24. Jennewein, C.; Sowa, R.; Faber, A.C.; Dildey, M.; von Knethen, A.; Meybohm, P.; Scheller, B.; Dröse, S.; Zacharowski, K. Contribution of Ninjurin1 to Toll-like receptor 4 signaling and systemic inflammation. *Am. J. Respir. Cell Mol. Biol.* **2015**, *53*, 656–663. [\[CrossRef\]](https://doi.org/10.1165/rcmb.2014-0354OC) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/25860173)
- <span id="page-16-13"></span>25. Zhou, X.; Yu, X.; Wan, C.; Li, F.; Wang, Y.; Zhang, K.; Feng, L.; Wen, A.; Deng, J.; Li, S.; et al. NINJ1 regulates platelet activation and PANoptosis in septic disseminated intravascular coagulation. *Int. J. Mol. Sci.* **2023**, *24*, 4168. [\[CrossRef\]](https://doi.org/10.3390/ijms24044168)
- <span id="page-16-14"></span>26. Wang, X.; An, P.; Gu, Z.; Luo, Y.; Luo, J. Mitochondrial metal ion transport in cell metabolism and disease. *Int. J. Mol. Sci.* **2021**, *22*, 7525. [\[CrossRef\]](https://doi.org/10.3390/ijms22147525)
- <span id="page-16-15"></span>27. Jomova, K.; Makova, M.; Alomar, S.Y.; Alwasel, S.H.; Nepovimova, E.; Kuca, K.; Rhodes, C.J.; Valko, M. Essential metals in health and disease. *Chem. Biol. Interact.* **2022**, *367*, 110173. [\[CrossRef\]](https://doi.org/10.1016/j.cbi.2022.110173)
- <span id="page-16-16"></span>28. Kokilambigai, K.S.; Kavitha, J.; Seetharaman, R.; Lakshmi, K.S.; Sai Susmitha, A. Analytical and bioanalytical techniques for the quantification of the calcium channel blocker—Amlodipine: A critical review. *Crit. Rev. Anal. Chem.* **2021**, *51*, 754–786. [\[CrossRef\]](https://doi.org/10.1080/10408347.2020.1772036)
- <span id="page-16-17"></span>29. Trikudanathan, G.; Wolbrink, D.R.J.; van Santvoort, H.C.; Mallery, S.; Freeman, M.; Besselink, M.G. Current concepts in severe acute and necrotizing pancreatitis: An evidence-based approach. *Gastroenterology* **2019**, *156*, 1994–2007. [\[CrossRef\]](https://doi.org/10.1053/j.gastro.2019.01.269)
- <span id="page-16-18"></span>30. Agupitan, A.D.; Neeson, P.; Williams, S.; Howitt, J.; Haupt, S.; Haupt, Y. P53: A guardian of immunity becomes its saboteur through mutation. *Int. J. Mol. Sci.* **2020**, *21*, 3452. [\[CrossRef\]](https://doi.org/10.3390/ijms21103452)
- <span id="page-16-19"></span>31. Chen, Q.; Xin, G.; Li, S.; Dong, Y.; Yu, X.; Wan, C.; Wei, Z.; Zhu, Y.; Zhang, K.; Wang, Y.; et al. Berberine-mediated REDD1 down-regulation ameliorates senescence of retinal pigment epithelium by interrupting the ROS-DDR positive feedback loop. *Phytomedicine* **2022**, *104*, 154181. [\[CrossRef\]](https://doi.org/10.1016/j.phymed.2022.154181)
- <span id="page-16-21"></span>32. Jeon, S.; Kim, T.K.; Jeong, S.J.; Jung, I.-H.; Kim, N.; Lee, M.-N.; Sonn, S.-K.; Seo, S.; Jin, J.; Kweon, H.Y.; et al. Anti-inflammatory actions of soluble Ninjurin-1 ameliorate atherosclerosis. *Circulation* **2020**, *142*, 1736–1751. [\[CrossRef\]](https://doi.org/10.1161/CIRCULATIONAHA.120.046907) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/32883094)
- <span id="page-16-22"></span>33. Huang, Y.; Ren, H.; Gao, X.; Cai, D.; Shan, H.; Bai, J.; Sheng, L.; Jin, Y.; Zhou, X. Amlodipine improves spinal cord injury repair by inhibiting motoneuronal apoptosis through autophagy upregulation. *Spine* **2022**, *47*, E570–E578. [\[CrossRef\]](https://doi.org/10.1097/BRS.0000000000004310) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/34923548)
- <span id="page-16-23"></span>34. Haria, M.; Wagstaff, A.J. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. *Drugs* **1995**, *50*, 560–586. [\[CrossRef\]](https://doi.org/10.2165/00003495-199550030-00009) [\[PubMed\]](https://www.ncbi.nlm.nih.gov/pubmed/8521773)
- <span id="page-16-24"></span>35. Perides, G.; van Acker, G.J.D.; Laukkarinen, J.M.; Steer, M.L. Experimental acute biliary pancreatitis induced by retrograde infusion of bile acids into the mouse pancreatic duct. *Nat. Protoc.* **2010**, *5*, 335–341. [\[CrossRef\]](https://doi.org/10.1038/nprot.2009.243)
- <span id="page-16-25"></span>36. Shen, Y.; Wen, L.; Zhang, R.; Wei, Z.; Shi, N.; Xiong, Q.; Xia, Q.; Xing, Z.; Zeng, Z.; Niu, H.; et al. Dihydrodiosgenin protects against experimental acute pancreatitis and associated lung injury through mitochondrial protection and PI3K $\gamma$ /Akt inhibition. *Br. J. Pharmacol.* **2018**, *175*, 1621–1636. [\[CrossRef\]](https://doi.org/10.1111/bph.14169)
- <span id="page-17-0"></span>37. Zhang, X.; Xin, G.; Li, S.; Wei, Z.; Ming, Y.; Yuan, J.; Wen, E.; Xing, Z.; Yu, K.; Li, Y.; et al. Dehydrocholic acid ameliorates sodium taurocholate-induced acute biliary pancreatitis in mice. *Biol. Pharm. Bull.* **2020**, *43*, 985–993. [\[CrossRef\]](https://doi.org/10.1248/bpb.b20-00021)
- <span id="page-17-1"></span>38. Qiao, Y.; Wang, L.; Hu, T.; Yin, D.; He, H.; He, M. Capsaicin protects cardiomyocytes against lipopolysaccharide-induced damage via 14-3-3γ-mediated autophagy augmentation. *Front. Pharmacol.* **2021**, *12*, 659015. [\[CrossRef\]](https://doi.org/10.3389/fphar.2021.659015)

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.